

Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry

journal homepage: http://www.elsevier.com/locate/ejmech



Original article

Antifungal activity of oligochitosans (short chain chitosans) against some *Candida* species and clinical isolates of *Candida albicans*: Molecular weight—activity relationship



Sergey N. Kulikov^a, Svetlana A. Lisovskaya^a, Pavel V. Zelenikhin^b, Evgeniya A. Bezrodnykh^c, Diana R. Shakirova^b, Inesa V. Blagodatskikh^c, Vladimir E. Tikhonov^{c,*}

- ^a Kazan Scientific Research Institute of Epidemiology and Microbiology, Bolshaya Krasnaya St. 67, Kazan 420015, Russia
- ^b Kazan Federal University, Kremlyovskaya St. 18, Kazan 420008, Russia
- ^c A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov St. 28, Moscow 119991, Russia

ARTICLE INFO

Article history:
Received 13 March 2013
Received in revised form
13 December 2013
Accepted 18 December 2013
Available online 28 December 2013

Keywords: Chitosan Oligochitosan Activity Candida Hyphae TEM Cytometry

ABSTRACT

A series of oligochitosans (short chain chitosans) prepared by acidic hydrolysis of chitosan and characterized by their molecular weight, polydispersity and degree of deacetylation were used to determine their anticandidal activities. This study has demonstrated that oligochitosans show a high fungistatic activity (MIC 8–512 µg/ml) against *Candida* species and clinical isolates of *Candida albicans*, which are resistant to a series of classic antibiotics. Flow cytometry analysis showed that oligochitosan possessed a high fungicidal activity as well. For the first time it was shown that even sub-MIC oligochitosan concentration suppressed the formation of *C. albicans* hyphal structures, cause severe cell wall alterations, and altered internal cell structure. These results indicate that oligochitosan should be considered as a possible alternative/additive to known anti-yeast agents in pharmaceutical compositions.

© 2014 Elsevier Masson SAS. All rights reserved.

1. Introduction

The ascomycete yeast *Candida* is the most common cause of opportunistic mycosis worldwide.

Among Candida species, Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, Candida kruisei, Candida scotti, and Candida guilliermondii are the most widespread ones. Candida species can be found in the oral cavity, throat, gastrointestinal tract, vagina, nails, and skin, and they are responsible for most (>91%) yeast infections with *C. albicans* being their major cause [1]. Over the last decades, the predominant pathogenic Candida species have changed, and infections caused by nonalbicans Candida species have grown increasingly [2,3]. Conversely, the prominence of non-albicans, such as *C. kruisei*,

C. parapsilosis and *C. tropicalis*, has increased their antibiotic resistance bringing challenges for effective antifungal therapy [4,5].

Moreover, misuse of antibiotics and the growing number of diseases caused by fungi not susceptible to antibiotics have increased problems with human allergy and have become a big problem globally [6], especially taking into account that there are a limited number of antifungal drugs [3]. Therefore, there is a need for new non-toxic fungicides which would be active against invasive and noninvasive human pathogens and could, at least, reduce the level of administration and side effects of classic antibiotics [7].

Chitin, $poly[\beta-(1 \to 4)-2-acetamido-2-deoxy-deo$

^{*} Corresponding author. Tel.: +7 4991359375; fax: +7 4991355085. E-mail address: tikhon@ineos.ac.ru (V.E. Tikhonov).